Actemra 80 mg vial 5 ml

Description

ACTEMRA ^® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. It is manufactured by Roche.

ACTEMRA ^® (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of:

Rheumatoid Arthritis :

Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Additional Information

Actemra (tocilizumab) is a humanized anti IL-6 receptor monoclonal antibody. It binds specifically to IL-6 receptors. IL-6 is a pro-inflammatory cytokine produced by a variety of cell types, including T- and B-cells, lymphocytes, monocytes and fibroblasts.

Actemra is specifically indicated for the treatment of active systemic juvenile idiopathic arthritis in patients two years of age and older.

Actemra is supplied as a solution for intravenous infusion. The recommended dose for patients with systemic juvenile idiopathic arthritis is as follows:
patients less than 30 kg weight: 12 mg per kg once every two weeks as a 60-minute single intravenous drip infusion
patients at or above 30 kg weight: 8 mg per kg once every two weeks as a 60-minute single intravenous drip infusion.